Sustained Virologic Response
"Sustained Virologic Response" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The continuous, long-term suppression of VIRAL LOAD, generally to undetectable levels, as the result of treatment with ANTIVIRAL AGENTS.
| Descriptor ID |
D000072230
|
| MeSH Number(s) |
E01.789.800.570 N04.761.559.590.800.665 N05.715.360.575.575.800.665
|
| Concept/Terms |
Sustained Virologic Response- Sustained Virologic Response
- Response, Sustained Virologic
- Sustained Virologic Responses
- Virologic Response, Sustained
- Sustained Viral Suppression
- Suppression, Sustained Viral
- Sustained Viral Suppressions
|
Below are MeSH descriptors whose meaning is more general than "Sustained Virologic Response".
Below are MeSH descriptors whose meaning is more specific than "Sustained Virologic Response".
This graph shows the total number of publications written about "Sustained Virologic Response" by people in this website by year, and whether "Sustained Virologic Response" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 7 | 12 | 19 |
| 2017 | 8 | 10 | 18 |
| 2018 | 8 | 17 | 25 |
| 2019 | 7 | 17 | 24 |
| 2020 | 3 | 14 | 17 |
| 2021 | 1 | 14 | 15 |
| 2022 | 1 | 6 | 7 |
| 2023 | 1 | 4 | 5 |
| 2024 | 1 | 8 | 9 |
| 2025 | 0 | 1 | 1 |
Below are the most recent publications written about "Sustained Virologic Response" by people in Profiles.
-
A single-site randomized controlled trial of partner navigation to HCV treatment for people who inject drugs: a study protocol for the You're Empowered for Treatment Initiation (YETI) partner trial. Trials. 2025 Jan 22; 26(1):26.
-
Cytokine trajectory over time in men and women with HIV on long-term antiretroviral therapy. AIDS. 2025 Jan 01; 39(1):1-10.
-
Variability of Hepatitis C Treatment Cascade Outcomes among People Who Inject Drugs across Geographically Diverse Clinics in the US: The HERO Study. Viruses. 2024 Sep 30; 16(10).
-
Hepatitis C Virus Reinfection Among People Who Inject Drugs: Long-Term Follow-Up of the HERO Study. JAMA Netw Open. 2024 Aug 01; 7(8):e2430024.
-
Impact of financial incentives on viral suppression among adults initiating HIV treatment in Tanzania: a hybrid effectiveness-implementation trial. Lancet HIV. 2024 Sep; 11(9):e586-e597.
-
Effect of self-efficacy among persons who inject drugs treated with direct-acting antivirals on Hepatitis C treatment initiation, duration, completion, adherence, and cure. Drug Alcohol Depend. 2024 Sep 01; 262:111384.
-
Taurine-conjugated bile acids and their link to hepatic S1PR2 play a significant role in hepatitis C-related liver disease. Hepatol Commun. 2024 07 01; 8(7).
-
Success of the US Veterans Health Administration's Hepatitis C Virus Care Continuum in the Direct-acting Antiviral Era. Clin Infect Dis. 2024 Jun 14; 78(6):1571-1579.
-
Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection. J Pediatr Gastroenterol Nutr. 2024 Jun; 78(6):1342-1354.
-
Overreporting of adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs in the HERO study. BMC Infect Dis. 2024 Feb 23; 24(1):251.